SCHEMBL3255338

SCHEMBL3255338

O=C(O)Cc1cnc(NS(=O)(=O)c2ccc(F)cc2F)s1

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.43
KCNH2 Q12809 1/20 0.42
PIK3CB P42338 1/20 0.42
POLB P06746 1/20 0.42
PIK3C3 Q8NEB9 5/20 0.41
HSD11B1 P28845 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CD O00329 1/20 0.40
KDM4E B2RXH2 1/20 0.40
CXCR4 P61073 1/20 0.40
SCN9A Q15858 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3254082 0.89 HSD11B1 (0.46) BRD4PIK3C3HSD11B1SCN9A
SCHEMBL3253473 0.89 NMT1 (0.44) PIK3C3HSD11B1SCN9A
SCHEMBL3254728 0.86 MEP1B (0.46) BRD4POLBHSD11B1KDM4E
SCHEMBL3253302 0.85 HSD11B1 (0.42) HSD11B1SCN9A
SCHEMBL3258378 0.85 HSD11B1 (0.41) HSD11B1SCN9A
SCHEMBL3252428 0.84 HSD11B1 (0.38) HSD11B1KDM4ESCN9A
SCHEMBL3251733 0.83 ALDH1A1 (0.46)
SCHEMBL3258413 0.79 HSD11B1 (0.47) HSD11B1
SCHEMBL3253445 0.78 SCD (0.46) HSD11B1SCN9A
SCHEMBL3256750 0.78 HSD11B1 (0.48) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 EP claimed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 US claimed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 US claimed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2019075394-A1 COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME VANDERKLISH PETER (US) 2019-04-18 WO disclosed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 US disclosed
US-7094792-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-08-22 US disclosed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 US disclosed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 BRD4 4628/4885KCNH2 3915/4885PIK3CB 1467/4885
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 BRD4 3989/4885KCNH2 4311/4885PIK3CB 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.